StockNews.AI

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

StockNews.AI • 1 minute

DCPHTKPHBIOCERS
High Materiality8/10

Information

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-st...

Original source

AI Summary

Disc Medicine, Inc. (NASDAQ:IRON) has appointed Lisa Amaya Price as Chief Human Resources Officer, signaling enhanced hiring efforts to support impending commercialization of its hematologic therapies. This strategic leadership hire aims to optimize the organization's growth and talent acquisition as Disc expands its product portfolio.

Sentiment Rationale

Strategic leadership changes often lead to improved organizational effectiveness. Historical examples show that strong HR management significantly contributes to the successful execution of commercialization strategies, thus enhancing investor confidence.

Trading Thesis

Expect a potential bullish momentum in IRON as commercialization plans advance within 12 months.

Market-Moving

  • Appointment could lead to improved workforce capabilities and efficiency.
  • Increased hiring aligns with upcoming product launches and commercialization activities.
  • Enhanced HR leadership may attract top talent, boosting innovation.
  • STRONG focus on hematologic diseases positions IRON for strategic market advantage.

Key Facts

  • Disc Medicine appoints Lisa Amaya Price as new Chief HR Officer.
  • Ms. Amaya Price has 25 years of HR experience in biopharma.
  • Increased hiring signals preparation for commercialization of treatments.
  • New HR leadership could enhance organizational talent and scalability.
  • Company continues to focus on hematologic disease therapies.

Companies Mentioned

  • Deciphera Pharmaceuticals (DCPH): Amaya Price previously contributed to Deciphera’s integration into ONO, showcasing her industry experience.
  • Takeda Pharmaceuticals (TKPH): Her prior HR leadership roles at Takeda enhance credibility in biopharma talent management.

Corporate Developments

The article fits within the 'Corporate Developments' category as it highlights strategic leadership changes that may impact operational efficiency and future growth trajectories. Enhancements in HR are particularly relevant for clinical-stage companies like IRON approaching commercialization phases.

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

Date: January 12, 2026 | Source: GlobeNewsWire

Overview of the Appointment

Disc Medicine, Inc. (NASDAQ: IRON), a biopharmaceutical company focused on developing novel treatments for serious hematologic diseases, has announced the appointment of Lisa Amaya Price, MBA as the company’s new Chief Human Resources Officer (CHRO). With over 25 years of experience in human resources and organizational leadership, Ms. Amaya Price brings a wealth of knowledge to the role, having worked with various commercial-stage companies.

Executive Insights and Future Directions

John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, emphasized the importance of this strategic appointment by stating, “As we move towards commercialization, we have meaningfully increased hiring to support these efforts. Lisa will play a central role in building a strong, scalable organization by attracting, developing, and retaining exceptional talent across the business.”

Ms. Amaya Price expressed her excitement about joining before a critical phase in the company’s operations: “The opportunity to help build and scale a team while preparing to deliver a much-needed therapy to patients with significant unmet needs is incredibly motivating.”

Professional Background and Previous Roles

Before joining Disc Medicine, Ms. Amaya Price served as the Senior Vice President and Chief HR Officer at Deciphera, where she played a pivotal role during its integration with ONO Pharmaceuticals. Previously, she was the Chief People Officer at LGC Group, a global life science tools company. Her career also includes significant positions at Scholar Rock and Takeda Pharmaceuticals, where she was involved in organizational design and talent selection related to the acquisition of Shire Pharmaceuticals.

  • Earlier roles included senior HR positions at Biogen, Interpublic Group, Metro International, and American Financial Systems.
  • Her educational credentials include a BA from Bard College, an MA from Simmons College, and an MBA from Babson College.

Inducement Equity Award Details

In connection with her appointment, Disc Medicine has granted Ms. Amaya Price an inducement equity award comprising:

  • Option Award: An option to purchase 37,500 shares of the company's common stock at the closing price on the date of grant.
  • RSU Award: A restricted stock unit award for 25,000 shares of common stock.
  • Supplemental RSU Award: A restricted stock unit award for 4,000 shares of common stock.

The vesting schedules for these awards are structured to encourage long-term commitment to the company.

About Disc Medicine

Disc Medicine (NASDAQ: IRON) is dedicated to the discovery and commercialization of innovative treatments for serious hematologic diseases. The company aims to create a diverse portfolio of first-in-class therapeutic candidates targeting crucial biological pathways related to red blood cell health.

For further details, please visit www.discmedicine.com.

Forward-Looking Statements

This announcement contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including professional projections about the company’s plans and expectations for Ms. Amaya Price’s role. Investors should be cautious, as actual results may differ due to various risks and uncertainties.

Related News